List view / Grid view
A new clinical study by Pfizer Inc. and BioNTech SE, and Phase…
A new clinical study by Pfizer Inc. and BioNTech SE, and Phase II study by Moderna, are seeking to evaluate the immunogenicity and safety of Omicron-based vaccines and boosters.
Pfizer and BioNTech have announced the submission of initial data…
Pfizer and BioNTech have announced the submission of initial data to the US FDA to support booster dose of COVID-19 vaccine.
![Lines of vials labelled 'COVID-19 Vaccines' [Credit: Dimitris Barletis/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Covid-19-vaccines-2-1-300x278.jpg)
![Lines of vials labelled 'COVID-19 Vaccines' [Credit: Dimitris Barletis/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Covid-19-vaccines-2-1-e1614176959561.jpg)
New stability data could allow Pfizer and BioNTech’s COMIRNATY® COVID-19…
New stability data could allow Pfizer and BioNTech’s COMIRNATY® COVID-19 vaccine to be stored at normal refrigerated temperatures for up to two weeks.
Pfizer and BioNTech have initiated Phase I/II trials in the…
Pfizer and BioNTech have initiated Phase I/II trials in the US to determine the safety and optimal dose of four mRNA COVID-19 vaccine candidates.
A Phase I/II clinical trial for BioNTech's BNT162 vaccine programme to prevent COVID-19 infection has been granted…
A Phase I/II clinical trial for BioNTech's BNT162 vaccine programme to prevent COVID-19 infection has been granted approval in Germany.
